

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/40020 A1

(51) International Patent Classification⁷: **A61K 31/427**,
A61P 5/18, 19/08, 19/10

(21) International Application Number: PCT/GB01/05044

(22) International Filing Date:
14 November 2001 (14.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0027783.0 14 November 2000 (14.11.2000) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BUCKINGHAM,**
Robin, Edwin [GB/GB]; GlaxoSmithKline, New Frontiers
Science Park South, Third Avenue, Harlow, Essex CM19
5AW (GB).

(74) Agent: **GIDDINGS, Peter, John**; SmithKline Beecham,
Corporate Intellectual Property (CN9.25.1), 980 Great
West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL USE OF CERTAIN INSULIN SENSITIZERS OR PPAR-GAMMA AGONISTS

(57) Abstract: A use of certain insulin sensitiser or a PPAR γ agonist such as a compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A¹ represents a substituted or unsubstituted aromatic heterocyclyl group; R¹ represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R² and R³ each represent hydrogen, or R² and R³ together represent a bond; A² represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6, for the manufacture of a medicament for treatment and/or prophylaxis of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases.


NOVEL USE OF CERTAIN INSULIN SENSITIZERS OR PPAR-GAMMA AGONISTS

NOVEL USE

This invention relates to novel use of certain an insulin sensitisers and PPAR γ agonists, such as certain substituted thiazolidinedione derivatives and of pharmaceutical compositions containing such compounds.

European Patent Applications, Publication Numbers 0008203, 0139421, 0155845, 0177353, 0193256, 0207581 and 0208420 relate to thiazolidinedione derivatives which are disclosed as having hypoglycaemic and hypolipidaemic activity. Chem. Pharm. Bull 30 (10) 3580-3600 also relates to certain thiazolidinedione derivatives having hypoglycaemic and hypolipidaemic activities.

European Patent Application, Publication Number 0306228 discloses certain substituted thiazolidinedione derivatives of formula (A):



(A)

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

A^{1a} represents a substituted or unsubstituted aromatic heterocyclyl group;

R^{1a} represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

R^{2a} and R^{3a} each represent hydrogen, or R^{2a} and R^{3a} together represent a bond;

A^{2a} represents a benzene ring having in total up to five substituents; and


n' represents an integer in the range of from 2 to 6. Such compounds are disclosed *inter alia* as being useful for the treatment and/or prophylaxis of cardiovascular disease and certain eating disorders.

European Patent application, publication number 0783888 discloses the use of troglitazone and certain thiazolidinediones for the treatment of osteoporosis. EP0783888 defines the said certain thiazolidinediones by use of a formula (I) defined therein. The compounds of formula (I) of EP0783888 are referred to herein as "the compounds of formula (A)". The disclosures of EP0783888 are incorporated herein by reference.

It has now surprisingly been discovered that the compounds of EP0306228 are indicated to be of particular use of particular use in the treatment and/or prophylaxis of

diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases

Accordingly, the present invention provides the use of an insulin sensitiser, such as a compound of formula (I):



(I)

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

A¹ represents a substituted or unsubstituted aromatic heterocyclyl group;

R¹ represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

R² and R³ each represent hydrogen, or R² and R³ together represent a bond;

A² represents a benzene ring having in total up to five substituents; and

n represents an integer in the range of from 2 to 6, for the manufacture of a medicament for treatment and/or prophylaxis, especially treatment, of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease,

hyperparathyroidism and related diseases

In a further aspect there is provided a method for the treatment and/or prophylaxis, especially the treatment, of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases, which method comprises the administration of an effective, non-toxic amount of an insulin sensitiser, such as a compound of the above defined formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof.

There is also provided a pharmaceutical composition for use in the treatment and/or prophylaxis, especially the treatment, of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases, which composition comprises an insulin sensitiser, such as a compound of the above defined formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

A particular disease associated with loss of bone mass is osteoporosis. A particular disease associated with loss of bone mass is Paget's disease. A particular disease associated with loss of bone mass is hyperparathyroidism.

A suitable insulin sensitiser is a compound of the above defined formula (I).

5 Suitable aromatic heterocyclyl groups include substituted or unsubstituted, single or fused ring aromatic heterocyclyl groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen.

Favoured aromatic heterocyclyl groups include substituted or unsubstituted single ring aromatic heterocyclyl groups having 4 to 7 ring atoms, preferably 5 or 6 ring atoms.


10 In particular, the aromatic heterocyclyl group comprises 1, 2 or 3 heteroatoms, especially 1 or 2, selected from oxygen, sulphur or nitrogen.

Suitable values for A^1 when it represents a 5- membered aromatic heterocyclyl group include thiazolyl and oxazolyl, especially oxazolyl.


15 Suitable values for A^1 when it represents a 6- membered aromatic heterocyclyl group include pyridyl or pyrimidinyl.

Suitably R^2 and R^3 each represent hydrogen.


Preferably, A^1 represents a moiety of formula (a), (b) or (c):



(a)



(b)



(c)

20

wherein: R^4 and R^5 each independently represents a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group or when R^4 and R^5 are each attached to adjacent carbon atoms, then R^4 and R^5 together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by R^4 and R^5 together may be substituted or unsubstituted; and in the moiety of formula (a)

25

X represents oxygen or sulphur.


Aptly, A^1 represents a moiety of the abovedefined formula (a).

Aptly, A^1 represents a moiety of the abovedefined formula (b).

30

Aptly, A^1 represents a moiety of the abovedefined formula (c).

In one favoured aspect R^4 and R^5 together represent a moiety of formula (d):



(d)

wherein R^6 and R^7 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.

Suitably, R^6 and R^7 each independently represent hydrogen, halogen, alkyl or alkoxy.

Favourably, R^6 represents hydrogen. Favourably, R^7 represents hydrogen.

Preferably, R^6 and R^7 both represent hydrogen.


In a further favoured aspect R^4 and R^5 each independently represent hydrogen, alkyl or a substituted or unsubstituted phenyl group and more favourably, R^4 and R^5 each independently represent hydrogen, alkyl or phenyl.

Preferably, for the moiety of formula (a), R^4 and R^5 together represent the moiety of formula (d).

Preferably, for the moieties of formula (b) or (c), R^4 and R^5 both represent hydrogen.

It will be appreciated that the five substituents of A^2 include three optional substituents. Suitable optional substituents for the moiety A^2 include halogen, substituted or unsubstituted alkyl or alkoxy.

Favourably, A^2 represents a moiety of formula (e):




(e)

wherein R^8 and R^9 each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.

Suitably, R^8 and R^9 each independently represent hydrogen, halogen, alkyl or alkoxy. Preferably, R^8 and R^9 each represent hydrogen.

Favourably, X represents oxygen. Favourably, X represents sulphur.

In one preferred aspect the present invention provides a class of compounds, which fall wholly within the scope of formula (I), of formula (II):



(II)

or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a
 5 pharmaceutically acceptable solvate thereof, wherein A¹, R¹, R², R³, and n are as
 defined in relation to formula (I) and R⁸ and R⁹ are as defined in relation to formula (e).

Suitably, n represents an integer 2, 3 or 4, notably 2 or 3 and especially 2.

Suitably, R¹ represents hydrogen, alkyl, acyl, especially acetyl, or benzyl.

When R¹ represents an alkyl group, examples of such alkyl groups include methyl
 10 and isopropyl. Preferably, R¹ represents a methyl group.

As indicated above a compound of formula (I) may exist in one of several
 tautomeric forms, all of which are encompassed by the present invention. It will be
 appreciated that the present invention encompasses all of the isomeric forms of the
 compounds of formula (I) and the pharmaceutically acceptable salts thereof, including
 15 any stereoisomeric forms thereof, whether as individual isomers or as mixtures of
 isomers.

Suitable substituents for any heterocyclyl group include up to 4 substituents
 selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two
 substituents on adjacent carbon atoms, together with the carbon atoms to which they are
 20 attached, may form an aryl group, preferably a benzene ring, and wherein the carbon
 atoms of the aryl group represented by the said two substituents may themselves be
 substituted or unsubstituted.

When used herein the term 'aryl' includes phenyl and naphthyl optionally
 substituted with up to five, preferably up to three, groups selected from halogen, alkyl,
 25 phenyl, alkoxy, haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl,
 alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.

When used herein the term 'halogen' refers to fluorine, chlorine, bromine and
 iodine; preferably chlorine.

When used herein the terms 'alkyl' and 'alkoxy' relate to groups having straight or
 30 branched carbon chains, containing up to 12 carbon atoms.

When used herein the term 'acyl' includes alkylcarbonyl groups.

Suitable alkyl groups are C₁₋₁₂ alkyl groups, especially C₁₋₆ alkyl groups e.g.
 methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.

Suitable substituents for any alkyl group include those indicated above in relation to the term "aryl".

Suitable pharmaceutically acceptable salts include salts of the thiazolidinedione moiety, and, where appropriate, salts of carboxy groups.

5 Suitable pharmaceutically acceptable salts of the thiazolidinedione moiety include metal salts especially alkali metal salts such as the lithium, sodium and potassium salts.

 Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium
10 salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine
15 type such as pyridine, collidine or quinoline.

 Suitable pharmaceutically acceptable solvates include hydrates.

 The salts and/or solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures for example sodium salts may be prepared by using sodium methoxide in methanol.

20 Suitable pharmaceutically acceptable salts of the thiazolidinedione moiety include metal salts especially alkali metal salts such as the lithium, sodium and potassium salts.

 A preferred compound of formula (I) is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (herein after also referred to as "Compound (I)") or a tautomeric form thereof and/or a pharmaceutically acceptable salt
25 thereof and/or a pharmaceutically acceptable solvate thereof.

 A preferred salt of Compound (I) is a maleate salt as disclosed in International Application, publication number WO94/05659.

 As is known in the art Compound (I) is a PPAR γ agonist. Thus the invention also includes the use of a PPAR γ agonist, in the manufacture of a medicament for the
30 treatment and/or prophylaxis, especially the treatment, of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases.

 In a further aspect there is provided a method for the treatment and/or prophylaxis, especially the treatment, of diseases associated with loss of bone mass, such as
35 osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases, which method comprises the administration of an effective, non-toxic amount of a PPAR γ agonist.

There is also provided a pharmaceutical composition for use in the treatment and/or prophylaxis, especially the treatment, of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases, which composition comprises a PPAR γ agonist and a pharmaceutically acceptable carrier therefor.

The above mentioned insulin sensitisers do not include troglitazone or the compounds of formula (A) or pharmaceutically acceptable derivatives thereof.

The above mentioned PPAR γ agonists do not include troglitazone or the compounds of formula (A) or pharmaceutically acceptable derivatives thereof.

Suitable insulin sensitisers or PPAR γ agonists are thiazolidinediones.

Suitable insulin sensitisers or PPAR γ agonists are insulin sensitisers or PPAR γ agonists other than thiazolidinediones.

Suitable non-thiazolidinedione insulin sensitisers include the compounds of formula (I) of International application, publication number WO 97/31907 or a pharmaceutically acceptable derivative thereof. A particular compound of WO 97/31907 (or EP0888317) is 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-5-methyl-2-phenyl-oxazol-4-yl]-ethoxy}-phenyl}-propionic acid or a pharmaceutically acceptable derivative thereof, such as a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof.

The contents of WO 97/31907 (or EP0888317) are included herein by reference.

The insulin sensitisers or PPAR γ agonists mentioned herein are prepared according to methods known in the art including those disclosed in the above mentioned publications. Thus a compound of above defined formula (I) such as Compound (I), or the tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, may be prepared using the processes described in EP 0306228. The contents of EP 0306228 are incorporated herein by reference

As mentioned above the compounds of the invention are indicated as having useful therapeutic properties:

The insulin sensitisers or PPAR γ agonists of the invention such as a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.

The present invention further provides a method for the treatment of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases, in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.

Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range disclosed in the above mentioned publications, for example for a compound of the above defined formula (I) such as Compound (I), in the range of from 0.1 to 1000 mg, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg. The unit dosages of each of the compounds specifically mentioned herein

In the above mentioned treatments the insulin sensitisers or PPAR γ agonists of the invention such as the compound of the general formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be taken in doses, such as those described in the above mentioned publications including, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.

Particularly, the method comprises the administration of 2 to 4 , 4 to 8 or 8 to 12 mg of Compound (I) per day.

Particularly, the method comprises the administration of 2 to 4mg of Compound (I), especially when administered per day.

Particularly, the method comprises the administration of 4 to 8mg of Compound (I), especially when administered per day.

5 Particularly, the method comprises the administration of 8 to 12 mg of Compound (I), especially when administered per day.

Preferably, the method comprises the administration of 2 mg of Compound (I), especially when administered per day.

10 Preferably, the method comprises the administration of 4 mg of Compound (I), especially when administered per day.

Preferably, the method comprises the administration of 8 mg of Compound (I), especially when administered per day.

15 A further suitable compound for use in the present treatment is the thiazolidinedione insulin sensitiser 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione (or pioglitazone). Methods of preparation and formulation of this compound are known in the art, as for example is disclosed in European Application, Publication Number EP 0749751.

20 Suitable unit dosages of the actives include all the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.


25 The compositions are also formulated according to conventional methods, such as those disclosed in standard reference texts including the above mentioned reference texts and Harry's Cosmeticology (Leonard Hill Books).

30 The activity of compounds as agents effective in the treatment or prophylaxis of diseases associated with loss of bone mass are assessed using known methodology for example those disclosed in Wronski, T.J., Lowry, P.L., Walsh, C.C. and Ignaszewski L.A. 1985 "Skeletal alterations in ovariectomized rats." *Calcified Tissue International* 37:324-328). or Dunstan, C.R. and Boyce B.F. *Animal models for the investigation of the action of factors on bone metabolism* In: *Methods in Bone Biology*, eds: T.R. Arnett and B. Henderson, Chapman and Hall, 1998, pp 290-303.

Claims:

1. A use of an insulin sensitiser or a PPAR γ agonist such as a compound of formula (I):

5



(I)

- 10 or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:
- A¹ represents a substituted or unsubstituted aromatic heterocyclyl group;
- R¹ represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl
- 15 group;
- R² and R³ each represent hydrogen, or R² and R³ together represent a bond;
- A² represents a benzene ring having in total up to five substituents; and
- n represents an integer in the range of from 2 to 6, for the manufacture of a medicament for treatment and/or prophylaxis of diseases associated with loss of bone mass, such as
- 20 osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases, providing that the insulin sensitiser or PPAR γ agonist does not include troglitazone or the compounds of formula (A) or pharmaceutically acceptable derivatives thereof.
- 25 2. A use according to claim 1, wherein the disease associated with loss of bone mass is osteoporosis.
3. A use according to claim 1, wherein the disease associated with loss of bone mass is Paget's disease.
- 30 4. A use according to claim 1, wherein the disease associated with loss of bone mass is hyperparathyroidism.

INTERNATIONAL SEARCH REPORT

Inter application No
PC1/GB 01/05044

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/427 A61P5/18 A61P19/08 A61P19/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, PASCAL, EMBASE, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 61127 A (SUZUKI MASAMI ; ODAKA HIROYUKI (JP); TAKEDA CHEMICAL INDUSTRIES LTD) 19 October 2000 (2000-10-19) page 18, line 20 - line 23; claims 13,14 ---	1, 2, 5-7
Y	OKAZAKI R ET AL: "THIAZOLIDINEDIONES INHIBIT OSTEOCLAST-LIKE CELL FORMATION AND BONE RESORPTION IN VITRO" ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 140, no. 11, November 1999 (1999-11), pages 5060-5065, XP001007057 ISSN: 0013-7227 the whole document ---	1-7
Y	US 5 476 865 A (PANETTA JILL A ET AL) 19 December 1995 (1995-12-19) column 1, line 1 - line 65 --- ---/---	1-7
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the International filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the International filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>* & * document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">18 February 2002</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">11/03/2002</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Zimmer, B</div>

INTERNATIONAL SEARCH REPORT

Inter. Application No.
PCT/GB 01/05044

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>US 6 239 157 B1 (MBALAVIELE GABRIEL) 29 May 2001 (2001-05-29) claim 4</p> <p>-----</p>	7

INTERNATIONAL SEARCH REPORT

tion on patent family members

Inter application No
PCT/GB 01/05044

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0061127	A	19-10-2000	AU 3677900 A	14-11-2000
			EP 1169037 A2	09-01-2002
			WO 0061127 A2	19-10-2000
			JP 2000355550 A	26-12-2000
			NO 20014935 A	12-12-2001
US 5476865	A	19-12-1995	CA 2153213 A1	07-01-1996
			EP 0691129 A2	10-01-1996
			JP 8040897 A	13-02-1996
US 6239157	B1	29-05-2001	NONE	